New User:

-or-
Username:
Password:
Forgot your password?
News Breaks
November 6, 2009
07:33 EDTPRX
theflyonthewall.com: Par Pharmaceutical reports Q3 EPS 76c vs. consensus of 49c
Reports Q3 revenue $294.8M vs. consensus of $290.44M. :theflyonthewall.com



News For PRX From The Last 14 Days
Check below for free stories on PRX the last two weeks.
There are 2 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing.
February 8, 2012
09:29 EDTPRX
theflyonthewall.com: Intellipharmaceutics targeting 2012 FDA approval of generic Focalin XR
Intellipharmaceutics' (IPCI) goals for 2012 include: Obtain FDA approval of Intellipharmaceutics' generic version of Focalin XR; File two additional ANDAs with the FDA; Establish additional development/marketing alliances; Schedule a pre-IND meeting with FDA to discuss Rexista oxycodone clinical development plan; Complete manufacturing of clinical batches of Rexista oxycodone; and Initiate Phase I studies using clinical batches of Rexista oxycodone. Note that Intellipharmaceutics' in February the company completed private placement financing, and revenue from the amendment of the existing development and commercialization agreement between the Company and Par Pharmaceutical (PRX) to include additional strengths of Focalin XR generic products. Under the terms of the expanded agreement, Intellipharmaceutics received a cash payment from Par and will continue to receive a share of profits from any future sales of our generic versions of Focalin XR. :theflyonthewall.com

February 3, 2012
06:18 EDTPRX
theflyonthewall.com: LSV Asset Management reports 5.73% passive stake in Par Pharmaceutical

Subscribe for More Information
:theflyonthewall.com